1. A compound of formula I:
or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,
wherein, X+ represents,
for use in treating an eye disorder or complications associated therewith. 2. The compound as claimed in claim 1, which is selected from:

3. The compound as claimed in claim 1, wherein said eye disorder is selected from the group consisting of macular degeneration, cataract, glaucoma, diabetic retinopathy, dry eye, ocular neuritis, retinitis pigmentosa and presbyopia.
4. A pharmaceutical composition for treating an eye disorder or complications thereof, comprising at least one compound as claimed in any one of claims 1 to 2 and a pharmaceutically acceptable excipient.
5. The pharmaceutical composition as claimed in claim 4, wherein said composition is formulated for oral, nasal, topical, rectal, vaginal, aerosol or parenteral administration.

6. The pharmaceutical composition as claimed in claim 4, wherein said composition is a topical ophthalmic formulation.
7. The pharmaceutical composition as claimed in claim 4, wherein said composition is an ophthalmic drop formulation.
8. A method of synthesis of the compound as claimed in claim 1, the method comprising treating pilocarpine with lipoic acid.
9. A method of treating an eye disorder or complications thereof in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a compound of formula I
or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,
10. The method as claimed in claim 9, wherein said compound of formula I is selected from:

11. The method as claimed in claim 9, wherein said administering comprises oral, nasal, topical, rectal, vaginal, aerosol or parenteral administration of said compound of formula I.
12. The method as claimed in claim 9, wherein said compound of formula I is administered to said subject in combination with a pharmaceutically acceptable excipient.
13. The method as claimed in claim 9, wherein said compound of formula I is administered topically in a form of an eye drop, a swab, an ointment, a gel or a mist.
14. The method as claimed in claim 9, wherein said compound of formula I is administered topically to at least one eye of said subject.
15. The method as claimed in claim 9, wherein said therapeutically effective amount ranges from 0.001mg to 1000mg.
16. The method as claimed in claim 9, wherein said subject is a human.
17. The method as claimed in claim 9, wherein said eye disorder is selected from the group consisting of macular degeneration, cataract, glaucoma, diabetic retinopathy, dry eye, ocular neuritis, retinitis pigmentosa and presbyopia.
18. Use of a compound as claimed in any of claims 1 to 2 for manufacture of a medicament for treatment of an eye disorder or complications associated therewith.